XOStem, Inc Employee Directory

Biotechnology ResearchUnited States2-10 Employees

XOStem is on the leading edge of translational biochemistry, using our Stem Cell expertise to create the next generation treatment for Type 1 Diabetes and produce Engineered Exosomes. Our combination of commercially developed science, partnerships with key scientific institutions, and university validation, enables us to rapidly bring to market novel therapies to tangibly improve people’s lives. More applications utilizing our Stem Cell technology will follow.

Our engineered exosome science is bringing to market the next generation of exosomes for regenerative skin care, joint care, and other therapies. Our research, technology and assays encompass the best methods for exosome isolation, purity, and characterization. More importantly our science leads the new frontier of engineered exosomes that carry well-defined payloads for more successful outcomes.

Our bioscience device will contain insulin producing cells similar to islets found in a healthy pancreas. Our unique encapsulation technology protects our cells from the autoimmune attack that killed the islets in the patient’s pancreas. Our device eliminates the pricking, needles, sensors and ports used by traditional insulin injection.

Existing therapies for type 1 diabetes patients inject insulin using manual or automated methods, attempting to emulate pancreatic islet production of insulin. While better methods for monitoring and injection have been attempted, many drawbacks exist, and none control blood sugar levels to the tight level of natural islets. More importantly, the micro encapsulated islets combined with our macro device will control blood sugar levels to the same levels of a normal pancreas, minimizing the likelihood of the dreaded diabetes complications.

Our team has decades of experience refining our technology in the laboratory, we are now moving to alleviate type 1 diabetes in companion animals (Dogs and Cats), once our process has significant successful data, we will then move to humans.

Find XOStem, Inc employees' phone numbers or email addresses

XOStem, Inc Global Highlights

Location
Employees

North America
7

Minus sign iconPlus sign icon
  • United States Of America
    7

XOStem, Inc's Leadership

  • Stylized image of a person
    J. S.
    Founder & Ceo
    Phone icon
  • Stylized image of a person
    A. B.
    Research Technician
    Phone icon

Contact profiles from XOStem, Inc

Name
Title
Contact Info
Location
Last Update
  • Stylized image of a person
    J. S.
    Founder & Ceo
    Phone icon
    United StatesCalifornia
    May 29, 2025
  • Stylized image of a person
    A. B.
    Research Technician
    Phone icon
    United StatesCalifornia
    Apr 25, 2025

Frequently Asked Questions

What is XOStem, Inc known for?

Minus sign iconPlus sign icon
XOStem, Inc was founded in 2018 operates in the Biotechnology Research industry. The company's main headquarters is located in 17252 Armstrong Ave, Suite A Irvine, California 92614, US. Explore XOStem, Inc's company overview page for more information.

What is XOStem, Inc's most common email format?

Minus sign iconPlus sign icon
XOStem, Inc employees' email format typically follows the pattern of . Trying to find reliable and up-to-date employee contact data? Find more XOStem, Inc email formats with LeadIQ.

How many employees does XOStem, Inc have currently?

Minus sign iconPlus sign icon
XOStem, Inc has approximately 5 employees as of December 2025. These team members are located across 1 continents, including North America.

Who are XOStem, Inc's key employees and leadership?

Minus sign iconPlus sign icon

As of December 2025, XOStem, Inc's key employees include:

  • Founder & Ceo: J. S.
  • Research Technician: A. B.

Looking for contact data? Unlock accurate emails and phone numbers for your ideal prospects with LeadIQ.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.